Amyloidosis — Protein Types, Congo Red and Apple-Green Birefringence

Amyloid is a pathological extracellular deposit formed from misfolded proteins that assemble into insoluble fibrils. Different precursor proteins can produce a similar microscopic deposit because the fibrils share a characteristic cross-beta-sheet structure. Amyloidosis therefore names a family of disorders, not one protein or one disease mechanism. The common appearance makes detection possible, but identifying the precursor remains essential.

On routine haematoxylin and eosin staining, amyloid is amorphous, acellular and eosinophilic. Deposits can accumulate around vessels, within the interstitium and in affected organ compartments, distorting normal architecture. A pale pink extracellular deposit is a clue rather than definitive proof: other materials may also be eosinophilic, so a specific staining and diagnostic approach is needed.

The signature association is Congo red staining with apple-green birefringence under polarized light. These are linked observations, not interchangeable descriptions. The stained deposit is examined under ordinary illumination and with polarization, which demonstrates the characteristic optical behaviour. An image question should be read in terms of both the stain and the lighting method used to obtain it.

The beta-sheet configuration accounts for Congo red binding and the characteristic birefringence pattern. Electron microscopy demonstrates nonbranching fibrils, described in the current StatPearls amyloidosis chapter as approximately 7–12 nm in diameter. This is an ultrastructural observation, not the size of a cell or the thickness of a light-microscopy tissue section. Keep the unit nanometres attached to the number.

Technical preparation and the amount of sampled amyloid affect detection. A negative result from a convenient sampling site does not exclude disease when suspicion remains high. The stain should be interpreted by an experienced laboratory in the clinical context, with further sampling or typing when needed. Conversely, a positive stain does not remove the need to establish why the amyloid formed.

The leading A denotes amyloid, while the remaining part of the label points toward the precursor. AL is a light-chain process; AA is linked to the acute-phase protein serum amyloid A; ATTR names transthyretin. These labels carry more mechanistic information than the older terms primary, secondary, familial and senile. The old terms may appear in examination options, so translate them into proteins.

Do not confuse Aβ with Aβ2M. The former refers to beta-amyloid in Alzheimer-associated cerebral disease, while the latter refers to beta-two-microglobulin in dialysis-related disease. They share part of a written abbreviation but have different precursors and settings. Similarly, AA does not mean that immunoglobulin heavy or light chains are the precursor.

Protein names and anatomical distribution are separate axes. Systemic disease can affect multiple organs, while localized deposits arise in particular tissues or settings. A thyroid tumour with calcitonin-derived amyloid should not automatically be classified as systemic AL. The clinical question may ask for the stain, the protein, the underlying disorder or the organ pattern, and each requires a different level of answer.

AL amyloidosis arises from a clonal plasma cell process producing monoclonal immunoglobulin light chains. Misfolding and aggregation of these chains form the amyloid fibrils. Lambda light chains predominate, although kappa light chains can also produce disease. The key connection is a plasma cell clone, not a requirement for every patient to fulfil criteria for overt multiple myeloma.

The clone may be small but still generate a pathogenic protein. Organ injury reflects both deposition that disrupts tissue architecture and toxic effects of soluble light-chain aggregates. This explains why the severity of organ dysfunction cannot be estimated simply by the visible quantity of deposit or the size of a marrow clone. Suspected AL requires both assessment of the clone and confirmation and typing of the deposit.

AA amyloidosis develops when persistent inflammation increases production of serum amyloid A, an acute-phase protein synthesized by the liver. Chronic inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease, chronic infections and autoinflammatory conditions are relevant contexts. The causal link is sustained inflammatory drive, not a direct transformation of bacteria or inflammatory cells into amyloid.

Both types can involve the kidney and produce proteinuria or nephrotic syndrome. Renal involvement alone does not prove AA. A patient with a monoclonal protein and renal disease still needs tissue interpretation because the monoclonal protein may be incidental or may cause another renal lesion. The combination of clinical pattern, laboratory work-up and amyloid typing provides the diagnosis.

Transthyretin is a transport protein associated with thyroxine and retinol handling. Variant ATTR arises from pathogenic TTR variants that promote misfolding. Wild-type ATTR results from age-related deposition of structurally normal transthyretin. The wild-type form is therefore not simply an inherited disease discovered late. Genetic testing after an ATTR diagnosis helps distinguish variant from wild-type disease.

Cardiac involvement and peripheral or autonomic neuropathy are important ATTR patterns. Bilateral carpal tunnel syndrome may precede more obvious systemic manifestations. These clues should raise suspicion rather than independently establish the diagnosis. The presence of neuropathy does not mean every patient has the same mutation, organ distribution or treatment requirement; ATTR phenotypes are variable.

In long-term renal failure and dialysis-related amyloidosis, beta-two-microglobulin accumulates and deposits in tissues. It is a different precursor from transthyretin or immunoglobulin light chains. When a vignette explicitly links amyloid to prolonged dialysis, recall the protein first. Avoid assigning every amyloid problem in a patient with kidney disease to this type, because AL and AA can themselves cause renal failure.

Localized examples reinforce the distinction between stain and cause. Beta-amyloid is associated with Alzheimer disease, while calcitonin-derived amyloid may occur in medullary thyroid carcinoma. The latter arises in a tumour derived from thyroid parafollicular C cells. A Congo-red-positive thyroid stromal deposit therefore fits a different clinical mechanism from a systemic plasma cell disorder.

A common cardiac stem combines increased ventricular wall thickness on echocardiography with relatively low ECG voltage. This mismatch suggests an infiltrative process. However, low voltage is not universal, especially in ATTR, and a normal-voltage ECG does not exclude cardiac amyloid. The heart may also show conduction disease, arrhythmias, diastolic dysfunction and reduced exercise tolerance.

Echocardiographic strain may show relative apical sparing, a useful clue that is interpreted with the other findings. Cardiac MRI can provide additional tissue characterization. Imaging raises suspicion and assesses the organ phenotype; it does not identify a light-chain precursor merely because the walls appear thick. Cardiac involvement has major implications for urgency, prognosis and treatment tolerance.

Systemic clues are strongest when they converge: unexplained proteinuria, neuropathy, orthostatic symptoms and cardiac findings deserve a unifying assessment. Macroglossia and periorbital purpura are memorable AL associations but may be absent. A list of classic findings should therefore support recognition rather than become a requirement that every patient must satisfy.

The diagnostic tasks are to confirm amyloid, identify the precursor and evaluate involved organs. Abdominal fat-pad aspiration is a useful minimally invasive sampling approach in suspected systemic disease, particularly AL. Bone marrow assessment can investigate a plasma cell clone. If these sites do not show amyloid but suspicion remains high, an affected-organ biopsy may be needed.

A negative fat-pad result does not reliably exclude all amyloid types. Sensitivity depends on subtype, sampling and laboratory technique. Selecting the biopsy site therefore requires attention to diagnostic yield and procedural risk. Tissue from an affected organ may be informative, but it is not automatically the safest first specimen. The important exam distinction is between a convenient screening site and a conclusive answer in a persistently suspicious case.

Laser microdissection with mass-spectrometry-based proteomic analysis is considered the gold standard for identifying the amyloid precursor. Immunohistochemistry and immunofluorescence can also help, but ordinary appearance and Congo red alone cannot distinguish the protein categories. Type the deposit before assuming that a concurrent monoclonal gammopathy explains it.

In suspected cardiac amyloidosis, investigate a light-chain process with serum free light chains plus serum and urine immunofixation. These tests look for monoclonal immunoglobulin production. Serum protein electrophoresis alone is not a complete substitute for this evaluation. A positive monoclonal screen requires appropriate specialist assessment and may necessitate biopsy and typing.

Bone-tracer cardiac scintigraphy can support a nonbiopsy ATTR diagnosis in the appropriate setting after exclusion of a detectable monoclonal process. The imaging findings and monoclonal tests must be interpreted together. Positive tracer uptake should not automatically be called ATTR when monoclonal proteins are present; AL can interfere with this shortcut and requires a different diagnostic path.

This is a reasoning trap rather than merely an imaging fact. The patient may have wild-type ATTR and an unrelated monoclonal gammopathy, or may have AL cardiac amyloid. Coexistence of a monoclonal protein does not settle which protein formed the deposit. In uncertain settings, obtain expert evaluation and tissue typing instead of selecting chemotherapy or an ATTR treatment from one test alone.

Treatment aims to reduce production or deposition of the specific pathogenic protein while supporting affected organs. AL requires suppression of the plasma cell clone with specialist haematological treatment. AA management focuses on control of the underlying inflammatory or infectious driver. Treating inflammation does not remove the clonal source in AL; treating a plasma cell clone does not address every ATTR case.

For ATTR, treatment depends on the phenotype and specialist assessment. Transthyretin stabilizers, such as tafamidis in relevant cardiac disease, target protein instability; other approaches reduce transthyretin production in appropriate settings. Treatment choices evolve, so the durable revision principle is precursor-directed therapy. The existence of a named drug does not mean all subtypes, all organ patterns or all patients have the same indication.

Supportive care addresses cardiac, renal, neurological and other organ dysfunction, while the specialist team evaluates treatment tolerance and response. Early recognition matters because persistent amyloid production and organ injury can make treatment more difficult. A good exam answer connects the upstream protein source to the downstream organ syndrome and avoids treating Congo red positivity as a complete treatment prescription.